Translational Session
Treatment Development in IgA Nephropathy
November 04, 2023 | 04:30 PM - 06:00 PM
Location: Room 201, Pennsylvania Convention Center
Session Description
IgA nephropathy is a rare kidney disease that, until recently, had no treatment options. Over the last decade, a robust pipeline of treatment options for IgA nephropathy are in clinical trials. This session highlights patient perspective, trial design, emerging therapies, and the collaboration between the US Food and Drug Administration (FDA), investigators, and industry required to make new therapies possible.
ASN thanks the Kidney Health Initiative for assistance with this session.
Session support is provided by an educational grant from Travere Therapeutics, Inc.
Learning Objective(s)
- Examine the trial design and endpoints in IgA nephropathy
- Discuss the perspective of a parent whose child was diagnosed with IgA nephropathy
- Explain how collaborations among researchers, industry, and the FDA opened opportunities for new translational science
- Summarize emerging therapies in IgA nephropathy
Learning Pathway(s)
- Glomerular Diseases
- CKD Non-Dialysis
Moderators
Presentations
- Perspective and Journey of a Parent Diagnosed with IgA Nephropathy
04:30 PM - 04:50 PM
- Trial Design and Endpoints in IgA Nephropathy
04:50 PM - 05:10 PM
- Regulatory Pathways for Drug Development, Including the Accelerated Approval Pathway
05:10 PM - 05:30 PM
- Emerging Therapies in IgA Nephropathy
05:30 PM - 05:50 PM
- Q&A
05:50 PM - 06:00 PM